IP Library › Granted Patent US 11,560,390
Granted Patent B2
US 11,560,390 · App. 17/023,266 · Granted Jan 24, 2023

Compounds for the treatment of cancer and inflammatory disease

Inventors: Yaron R. Hadari (Harrison, NY); Luca Carta (Scarsdale, NY); Michael Schmertzler (St. Petersburg, FL); Theresa M. Williams (Harleysville, PA); Charles H. Reynolds (Austin, TX)
Assignee: SHY Therapeutics LLC
C07D495/04C07D221/04C07D239/94C07D265/30C07D271/06C07D401/04C07D401/12C07D401/14C07D407/14C07D409/14C07D413/14C07D417/14C07D471/04C07D473/30C07D487/04C07D495/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,560,390
App. No.
17/023,266
Granted
Jan 24, 2023
Kind
B2
Abstract

Provided herein are compounds that inhibit the phosphorylation of MAPK and thus are useful in compositions and methods for treating cancer and inflammatory disease.

Claims (6)

1. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

2. A method of treating or ameliorating one or more symptoms of cancer, comprising administering to a subject the compound or pharmaceutically acceptable salt thereof of claim 1 ; wherein the cancer is a solid tumor selected from the group consisting of hepatocellular carcinoma, prostate cancer, pancreatic cancer, ovarian cancer, and glioblastoma.

3. The method of claim 2 , wherein the solid tumor is pancreatic cancer.

4. A method of treating or ameliorating one or more symptoms of an inflammatory disease, comprising administering to a subject the compound or pharmaceutically acceptable salt thereof of claim 1 ; wherein the inflammatory disease is gastritis, schistosomiasis, cholangitis, chronic cholecystitis, pelvic inflammatory disease, chronic cervicitis, osteomyelitis, inflammatory bowel disease, reflux esophagitis, Barrett's esophagus, bladder inflammation (cystitis), asbestosis, silicosis, gingivitis, lichen planus, pancreatitis, protease mutation, lichen sclerosis, slaladenitis, bronchitis, Sjogren syndrome or IIashimoto's thyroiditis.

5. A pharmaceutical composition, comprising the compound or pharmaceutically acceptable salt thereof of claim 1 and a pharmaceutically acceptable carrier.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 7, 2022
From: HADARI, YARON R.; CARTA, LUCA; SCHMERTZLER, MICHAEL; WILLIAMS, THERESA M.; REYNOLDS, CHARLES H.
To: SHY THERAPEUTICS LLC
Reel/Frame 061347/0925 →
Continuity (4)
Division 16246027 · Jan 11, 2019
Continuation 15387349 · Dec 21, 2016
Provisional Application 62271185 · Dec 22, 2015
Related Publication 20220332725A1 · Oct 20, 2022